Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 5, 2005, Pages 713-721

  Carmona, Maria J C ^a   Malbouisson, L M S ^a   Pereira, V A ^a   Bertoline, M A ^a   Omosako, C E K ^a   Le Bihan, K B ^a   Auler, J C O ^a   Santos, S R C J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiopulmonary bypass; Pharmacokinetics; Propranolol

Indexed keywords

DOBUTAMINE; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; PROPRANOLOL;

ADULT; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER PROGRAM; CORONARY ARTERY BYPASS GRAFT; CORONARY HEMODYNAMICS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEMODILUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDUCED HYPOTHERMIA; ISCHEMIC HEART DISEASE; LIVER METABOLISM; MALE; POSTOPERATIVE PERIOD; STATISTICAL SIGNIFICANCE;

EID: 20944448466     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005000500008     Document Type: Article

References (31)

1. Ryan TJ, Antman EM, Brooks NH et al. (1999). 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Journal of the American College of Cardiology, 34: 890-911.
2. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W, Miller D & Mangano DT (1998). Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology, 88: 7-17.
3. Mangano DT, Layug EL, Wallace A & Tateo I (1996) Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. New England Journal of Medicine, 335: 1713-1720.
4. Sill JC, Nugent M, Moyer TP, Torres LE, Schaff HV & Tinker JH (1984). Influence of propranolol plasma levels on hemodynamics during coronary artery bypass surgery. Anesthesiology, 60: 455-463.
5. Slogoff S & Keats AS (1985). Does perioperative myocardial ischemia lead to postoperative myocardial infarction? Anesthesiology, 62: 107-114.
6. Boudoulas H, Lewis RP, Snyder GL, Karayannacos P & Vasko JS (1979). Beneficial effect of continuation of propranolol through coronary bypass surgery. Clinical Cardiology, 2: 87-91.
7. Mangano DT (1998). Adverse outcomes after surgery in the year 2001 - a continuing odyssey. Anesthesiology, 88: 561-564.
8. Miller RR, Olson HG, Amsterdam EA & Mason DT (1975). Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. New England Journal of Medicine, 293: 416-418.
9. McAllister Jr RG, Bourne DW, Tan TG, Erickson JL, Wachtel CC & Todd EP (1979). Effects of hypothermia on propranolol kinetics. Clinical Pharmacology and Therapeutics, 25: 1-7.
10. McAllister Jr RG & Tan TG (1980). Effect of hypothermia on drug metabolism. In vitro studies with propranolol and verapamil. Pharmacology, 20: 95-100.
11. Plachetka JR, Salomon NW & Copeland JG (1981). Plasma propranolol before, during, and after cardiopulmonary bypass. Clinical Pharmacology and Therapeutics, 30: 745-751.
12. Richecoeur J, Lu Q, Vieira SR, Puybasset L, Kalfon P, Coriat P & Rouby JJ (1999). Expiratory washout versus optimization of mechanical ventilation during permissive hypercapnia in patients with severe acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 160: 77-85.
13. Pereira VA, Bertoline MA, Carmona MJC, Auler Jr JOC & Santos SRCJ (2000). High performance liquid chromatography to determine propranolol in plasma. Drug accumulation in post-surgical patients. Brazilian Journal of Pharmaceutical Sciences, 36: 241-247.
14. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM & Paranandi L (1992). Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. Journal of the American Medical Association, 267: 2344-2348.
15. Pereira VA, Auler Jr JO, Carmona MJ, Mateus FH, Lanchote VL, Breimer DD & Santos SR (2000). A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography. Brazilian Journal of Medical and Biological Research, 33: 509-514.
16. Evans DA, Mahgoub A, Sloan TP, Idle JR & Smith RL (1980). A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics, 17: 102-105.
17. Wojcicki J, Wojciechowski G, Wojcicki M, Kostyrka R, Sterna R, Gawronska-Szklarz B, Pawlik A, Drozdzik M & Kozlowski K (2000). Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study. European Journal of Clinical Pharmacology, 56: 75-79.
18. Wojcicki J, Jaroszynska M, Drozdzik M, Pawlik A, Gawronska-Szklarz B & Sterna R (2003). Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharmaceutics and Drug Disposition, 24: 211-218.
19. Wojcicki J, Sulzyc-Bielicka V, Kutrzeba J, Gawronska-Szklarz B, Drozdzik M & Sterna Z (1999). Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. Journal of Clinical Pharmacology, 39: 826-833.
20. Meier J (1979). Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol. Cardiology, 64 (Suppl 1): 1-13.
21. Sager G, Jaeger R & Little C (1989). Binding of prazosin and propranolol at variable alpha 1-acid glycoprotein and albumin concentrations. British Journal of Clinical Pharmacology, 27: 229-234.
22. Routledge PA & Schand DG (1979). Clinical pharmacokinetics of propranolol. Clinical Pharmacokinetics, 4: 73-90.
23. Frishman WH & Alwarshetty M (2002). β-Adrenergic blockers in systemic hypertension. Clinical Pharmacokinetics, 41: 505-516.
24. Rosen DA & Rosen KR (1997). Elimination of drugs and toxins during cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia, 11: 337-340.
25. Mets B (2000). The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiologica Scandinavica, 44: 261-273.
26. Wood M, Shand DG & Wood AJ (1979). Propranolol binding in plasma during cardiopulmonary bypass. Anesthesiology, 51: 512-516.
27. Davies RF, Dube LM, Mousseau N, McGilveray I & Beanlands DS (1988). Perioperative variability of binding of lidocaine, quinidine, and propranolol after cardiac operations. Journal of Thoracic and Cardiovascular Surgery, 96: 634-641.
28. Holley FO, Ponganis KV & Stanski DR (1982). Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clinical Pharmacokinetics, 7: 234-251.
29. Okano N, Miyoshi S, Owada R, Fujita N, Kadoi Y, Saito S, Goto F & Morita T (2002). Impairment of hepatosplanchnic oxygenation and increase of serum hyaluronate during normothermic and mild hypothermic cardiopulmonary bypass. Anesthesia and Analgesia, 95: 278-286.
30. Kumle B, Boldt J, Suttner SW, Piper SN, Lehmann A & Blome M (2003). Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Annals of Thoracic Surgery, 75: 1558-1564.
31. Carmona MJC, Pereira VA, Bertolini MA, Malbouisson LMS, Le Bihan KB, Lopes MR, Auler Jr JOC & Santos SRCJ (2003). Atenolol and propranolol pharmacokinetics changes in patients undergoing coronary artery bypass surgery. European Journal of Anesthesiology, 20: A-530 (Abstract).